TSXV:SVA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Sernova Corp., a clinical-stage regenerative medicine therapeutics company, focuses on the development and commercializing of its proprietary Cell Pouch System and associated technologies, including the cell pouch and systemic and/or locally immune protected therapeutic cells and tissues. More Details


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has Sernova's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SVA has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-1.8%

SVA

11.1%

CA Biotechs

0.2%

CA Market


1 Year Return

5.9%

SVA

77.6%

CA Biotechs

-7.8%

CA Market

Return vs Industry: SVA underperformed the Canadian Biotechs industry which returned 77.6% over the past year.

Return vs Market: SVA exceeded the Canadian Market which returned -7.8% over the past year.


Shareholder returns

SVAIndustryMarket
7 Day-1.8%11.1%0.2%
30 Day-5.3%20.4%-1.1%
90 Day3.8%4.8%5.9%
1 Year5.9%5.9%77.6%77.6%-4.6%-7.8%
3 Year38.5%38.5%52.1%52.1%9.6%-1.0%
5 Year-12.9%-12.9%-6.3%-6.3%41.7%19.9%

Price Volatility Vs. Market

How volatile is Sernova's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Sernova undervalued compared to its fair value and its price relative to the market?

24.15x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate SVA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate SVA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: SVA is unprofitable, so we can't compare its PE Ratio to the XN Biotechs industry average.

PE vs Market: SVA is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SVA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SVA is overvalued based on its PB Ratio (24.1x) compared to the CA Biotechs industry average (6.3x).


Next Steps

Future Growth

How is Sernova forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

23.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sernova has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Sernova performed over the past 5 years?

-12.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SVA is currently unprofitable.

Growing Profit Margin: SVA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SVA is unprofitable, and losses have increased over the past 5 years at a rate of 12.4% per year.

Accelerating Growth: Unable to compare SVA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SVA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).


Return on Equity

High ROE: SVA has a negative Return on Equity (-261.47%), as it is currently unprofitable.


Next Steps

Financial Health

How is Sernova's financial position?


Financial Position Analysis

Short Term Liabilities: SVA's short term assets (CA$2.9M) exceed its short term liabilities (CA$992.2K).

Long Term Liabilities: SVA has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: SVA is debt free.

Reducing Debt: SVA has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SVA has sufficient cash runway for 6 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: SVA is forecast to have sufficient cash runway for 5 months based on free cash flow estimates, but has since raised additional capital.


Next Steps

Dividend

What is Sernova current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SVA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SVA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SVA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SVA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SVA's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

9.8yrs

Average board tenure


CEO

Philip Toleikis

11.42yrs

Tenure

CA$793,214

Compensation

Dr. Philip M. Toleikis, B.A., M.Sc., Ph.D., has been the Chief Executive Officer and the President of Sernova Corp. since April 28, 2009. Dr. Toleikis is a seasoned and Experienced biotechnology executive, ...


CEO Compensation Analysis

Compensation vs Market: Philip's total compensation ($USD602.25K) is above average for companies of similar size in the Canadian market ($USD178.19K).

Compensation vs Earnings: Philip's compensation has increased whilst the company is unprofitable.


Board Members

NamePositionTenureCompensationOwnership
Philip Toleikis
President11.42yrsCA$793.21k2.64%
CA$ 1.4m
James Parsons
Independent Director8.42yrsCA$74.62k0.11%
CA$ 58.0k
Frank Holler
Independent Chairman5.5yrsCA$102.41k0.13%
CA$ 67.5k
Norman Wong
Member of Scientific Advisory Board14.17yrsno datano data
Jeffrey Bacha
Independent Director11.92yrsCA$77.12k0.29%
CA$ 151.6k
Jannette Dufour
Member of Scientific Advisory Board14.08yrsno datano data
George King
Member of Scientific Advisory Boardno datano datano data
Clive Patience
Member of Scientific Advisory Board13.75yrsno datano data
Steven Paraskevas
Member of Scientific Advisory Board9.75yrsno datano data
Deborah Brown
Independent Director1.42yrsCA$27.06kno data
David Lillicrap
Member of Scientific Advisory Board1.67yrsno datano data
Anke Schulte
Member of Global Advisory Board0.17yrno datano data

9.8yrs

Average Tenure

55yo

Average Age

Experienced Board: SVA's board of directors are considered experienced (9.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Sernova Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sernova Corp.
  • Ticker: SVA
  • Exchange: TSXV
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$52.932m
  • Shares outstanding: 196.05m
  • Website: https://www.sernova.com

Location

  • Sernova Corp.
  • The Stiller Centre
  • 700 Collip Circle
  • London
  • Ontario
  • N6G 4X8
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SVATSXV (TSX Venture Exchange)YesCommon SharesCACADFeb 2000
SEOV.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDFeb 2000
PSHDB (Deutsche Boerse AG)YesCommon SharesDEEURFeb 2000

Biography

Sernova Corp., a clinical-stage regenerative medicine therapeutics company, focuses on the development and commercializing of its proprietary Cell Pouch System and associated technologies, including the ce ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/21 06:59
End of Day Share Price2020/09/18 00:00
Earnings2020/04/30
Annual Earnings2019/10/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.